Novel Molecular Triggers Underlie Valproate-induced Liver Injury and Its Alleviation by the Omega-3 Fatty Acid DHA: Role of Inflammation and Apoptosis
Overview
Affiliations
Background/aim: Hepatic injury is a hallmark adverse reaction to Valproate (VPA), a common used drug in the management of numerous CNS disorders, including epilepsy. DHA has a myriad of health benefits, including renal- and hepato-protective effects. Unfortunately, however, the underpinnings of such liver-pertinent VPA- and DHA-actions remain largely undefined. Accordingly, this study attempted to unveil the cellular and molecular triggers whereby VPA evokes, while DHA abates, hepatotoxicity.
Methods: We evaluated activity and/or expression of cellular markers of oxidative stress, inflammation, and apoptosis in rat liver, following treatment with VPA (500 mg/kg/day) with and without concurrent treatment with DHA (250 mg/kg/day) for two weeks.
Results And Conclusion: VPA promoted hepatic oxidative stress as evidenced by enhancing activity/expression of NADPH-oxidase and its subunits, a ROS-generator, and by accumulation of lipid-peroxides. Moreover, VPA enhanced hepatic phosphorylation/activation of mitogen-activated protein kinase (MAPK), and expression of cyclooxygenase-2(COX-2), as proinflammatory signals. Besides, VPA promoted hepatocellular apoptosis, as attested by enhanced expression of cleaved caspase-9 and increased number of TUNEL-positive hepatocytes. Lastly, VPA upregulated levels of hypoxia-inducible factor-1-alpha (HIF-1α), a multifaceted modulator of hepatocytic biology, and activity of its downstream antioxidant enzyme heme-oxygenase-1(HO-1). These changes were significantly blunted by co-administration of DHA. Our findings demonstrate that VPA activated NADPH-oxidase and HIF-1α to induce oxidative-stress and hypoxia as initiators of hepatic injury. These changes were further aggravated by up-regulation of inflammatory (MAPK and COX-2) and apoptotic cascades, but could be partly lessened by HO-1 activation. Concurrent administration of DHA mitigated all VPA-induced anomalies.
Protective effect of long-chain polyunsaturated fatty acids on hepatorenal syndrome in rats.
Duailibe J, Viau C, Saffi J, Fernandes S, Porawski M World J Nephrol. 2024; 13(3):95627.
PMID: 39351184 PMC: 11439093. DOI: 10.5527/wjn.v13.i3.95627.
Sun J, Zhang K, Yin Y, Qi Y, Li S, Sun H Toxics. 2023; 11(12).
PMID: 38133385 PMC: 10748282. DOI: 10.3390/toxics11120984.
Life factors acting on systemic lupus erythematosus.
Chen J, Liao S, Pang W, Guo F, Yang L, Liu H Front Immunol. 2022; 13:986239.
PMID: 36189303 PMC: 9521426. DOI: 10.3389/fimmu.2022.986239.
Alqarni F, Eweis H, Ali A, Alrafiah A, Alsieni M, Karim S Biomedicines. 2022; 10(1).
PMID: 35052847 PMC: 8773341. DOI: 10.3390/biomedicines10010168.
Al-Rafiah A, Mehdar K Behav Neurol. 2021; 2021:5549638.
PMID: 34149964 PMC: 8195670. DOI: 10.1155/2021/5549638.